Legal & General Group Plc reduced its position in shares of Glaukos Corporation (NYSE:GKOS) by 1.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 4,076 shares of the medical instruments supplier’s stock after selling 73 shares during the period. Legal & General Group Plc’s holdings in Glaukos Corporation were worth $209,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. William Blair Investment Management LLC boosted its position in Glaukos Corporation by 5.3% in the first quarter. William Blair Investment Management LLC now owns 2,064,444 shares of the medical instruments supplier’s stock worth $105,906,000 after buying an additional 104,670 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Glaukos Corporation by 43.6% in the first quarter. Alliancebernstein L.P. now owns 1,291,882 shares of the medical instruments supplier’s stock valued at $66,274,000 after buying an additional 392,476 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Glaukos Corporation by 73.2% in the first quarter. Wells Fargo & Company MN now owns 1,156,562 shares of the medical instruments supplier’s stock valued at $59,332,000 after buying an additional 488,730 shares in the last quarter. State Street Corp boosted its position in shares of Glaukos Corporation by 6.9% in the fourth quarter. State Street Corp now owns 281,407 shares of the medical instruments supplier’s stock valued at $9,653,000 after buying an additional 18,183 shares in the last quarter. Finally, OppenheimerFunds Inc. bought a new position in shares of Glaukos Corporation during the first quarter valued at about $8,419,000. Hedge funds and other institutional investors own 89.63% of the company’s stock.

Glaukos Corporation (GKOS) traded up 3.28% during midday trading on Friday, reaching $37.50. 267,533 shares of the company traded hands. Glaukos Corporation has a one year low of $28.26 and a one year high of $52.49. The company has a 50 day moving average price of $40.38 and a 200-day moving average price of $43.21. The stock’s market capitalization is $1.29 billion.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/08/12/legal-general-group-plc-has-209000-position-in-glaukos-corporation-nysegkos.html.

Several brokerages recently issued reports on GKOS. Zacks Investment Research upgraded shares of Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 price target on the stock in a research report on Tuesday, July 4th. Roth Capital reduced their price target on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. BidaskClub upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. TheStreet cut shares of Glaukos Corporation from a “c” rating to a “d+” rating in a research report on Wednesday, May 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $54.00 price target on shares of Glaukos Corporation in a research report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $52.33.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.